ADAR1 Capital Management LLC purchased a new position in Eledon Pharmaceuticals, Inc. (NASDAQ: ELDN)

Eledon Pharma (NASDAQ:ELDN) reported quarterly losses of $(0.27) per share which missed the analyst

Successful End-of-Phase 2 meeting with FDA supports advancement of tegoprubart into a global Phase 3

Eledon Pharmaceuticals (ELDN) is rated Buy, with tegoprubart showing strong promise post-Phase 2 in

Wall Street analysts upgraded Fortinet, Goldman Sachs, Adaptive Biotechnologies, and Five Below, wit

Top Wall Street analysts change outlook on top stocks. For analyst rating changes, see https://www.b

Rodman & Renshaw analyst Seema Sheoran initiates coverage on Eledon Pharmaceuticals (NASDAQ:E

Gainers Q32 Bio (NASDAQ:QTTB) stock moved upwards by 44.4% to $16.19 during Friday's after-mark

The FDA provided clarity regarding the regulatory pathway toward launching a clinical trial of NCEL-

Eledon has established the regulatory framework for its Phase 3 kidney transplantation program and p

AUSTIN, Texas & IRVINE, Calif.--(BUSINESS WIRE)--Natera, Inc. (Nasdaq: NTRA), a global leader in cel

Eledon Pharmaceuticals, Inc. (ELDN) Discusses Updated Long-term Data From Phase 2 BESTOW Clinical Tr

Tegoprubart-treated patients maintained higher mean eGFR over time, including a statistically signif

Eledon Presents Long-Term Phase 2 BESTOW Results at ATC Showing Sustained Higher Kidney Function and

Here is how Eledon Pharmaceuticals, Inc. (ELDN) and Galderma Group AG - Unsponsored ADR (GALDY) have

Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today announced updated results from a

– All 12 patients in study (100%) achieved insulin independence, producing their own insulin and no

Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today announced that updated results f

IRVINE, Calif. , June 04, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (Nasdaq:

Here is how BillionToOne (BLLN) and Eledon Pharmaceuticals, Inc. (ELDN) have performed compared to t

NewcelX submitted an FDA Pre-IND package for NCEL-101 to advance its type 1 diabetes treatment into

Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today announced that the Company will

IRVINE, Calif., May 20, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: EL

Eledon Pharma (NASDAQ:ELDN) reported quarterly losses of $(0.33) per share which missed the analyst

100% insulin independence achieved in 10 patients with type 1 diabetes treated with tegoprubart foll

https://www.sec.gov/Archives/edgar/data/1404281/000119312526201426/d79008ds3.htm

NewcelX reports 2025 results, highlights NCEL-101 progress, $3.4 million financing potential, and pl

NewcelX Ltd. (NASDAQ:NCEL),– NewcelX Ltd. (NASDAQ:NCEL), a clinical-stage regenerative medicine comp

ZURICH, Switzerland, April 20, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. (Nasdaq: NCEL),- NewcelX Ltd. (

Shares of Eledon Pharmaceuticals, Inc. (NASDAQ: ELDN - Get Free Report) have been given an average r

Eledon Pharma (NASDAQ:ELDN) reported quarterly losses of $(0.10) per share which beat the analyst co

Reported updated results from 12 patients with type 1 diabetes treated with tegoprubart following is

Eledon Pharmaceuticals remains a "Strong Buy" following positive phase 2 BESTOW results for tegoprub

Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today announced updated results from a

IRVINE, Calif., March 10, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ:

The collaboration is designed to advance combination strategies integrating NewcelX's lead progr

Collaboration Integrates Stem-Cell-Derived Islets with Targeted Immune Modulation ZURICH, Switzerlan

Data from eight participants continue to support safety and tolerability profile of tegoprubartMean

Eledon Pharmaceuticals, Inc. ("Eledon") (Nasdaq: ELDN) today announced a summary of 2025 acc